Dose-dense @entity4349 -based chemotherapy for XXXX .

@entity632 @entity1 @entity172 @entity0 @entity1261 @entity1722 @entity4349 @entity786 @entity3052 @entity1398 @entity8566 @entity204 @entity1487
PURPOSE: Theoretical considerations and clinical experience suggest that dose-dense chemotherapy may be superior to other approaches using the same drugs. We studied a dose-dense combination of @entity632 and @entity786 , with or without @entity1487 , as adjuvant therapy. @entity1 AND METHODS: @entity1 with resected @entity0 were treated if they were node-positive and @entity172 receptor-negative, positive for overexpression of @entity1722 , or had four or more involved nodes. @entity632 was given weekly to a total dose of 480 mg/m(2). @entity786 60 mg/m(2) was given daily by mouth during the period of @entity632 treatment. The first 30 @entity1 received @entity1487 at 300 mg/m(2)/wk intravenously concurrently with @entity632 administration. In the last 22, it was omitted because of symptomatic @entity8566 in the majority of @entity1 . Filgrastim (granulocyte colony-stimulating factor [ @entity1261 ]) was administered during chemotherapy every day except the day of intravenous administration and continued until 1 week after the completion of the chemotherapy. RESULTS: Between October 20, 1992, and June 10, 1997, we enrolled 52 @entity1 . The mean delivered dose-intensity for @entity632 was 18.6 mg/m(2)/wk. Hospitalization was required in 6% of @entity1 for reversible @entity1398 . There were no acute treatment-related @entity204 , but one @entity1 subsequently died of @entity3052 with a characteristic translocation for @entity4349 -related exposure. At 5 years, the event-free survival was 86% for all @entity1 (95% confidence interval, 75% to 95%). CONCLUSION: Continuous dose-dense chemotherapy with @entity1261 support produced encouraging results, which seem to be superior to those expected with "standard" @entity632 and @entity786 chemotherapy. It deserves a test in the form of a randomized trial where this approach to @entity4349 -based treatment is compared with intermittent administration.
